What is TIGLUTIK?

TIGLUTIK is the only formulation of riluzole approved by the FDA for both oral and PEG tube use. One dose of TIGLUTIK 50 mg (10 mL) (2 teaspoons) is equivalent to one RILUTEK® (riluzole) 50 mg tablet, and it is taken twice a day, every 12 hours. TIGLUTIK has a mildly thick consistency and developed to be easy to swallow or use with a PEG tube. The American Academy of Neurology recommends that riluzole should be offered to all patients to slow the progression of ALS. Patients should discuss with their physician starting TIGLUTIK as soon as possible.

TIGLUTIK is for People Who Have Difficulty Swallowing

ALS often affects the nerves and muscles that help us swallow. Approximately 85% of people with ALS develop a medical condition called dysphagia (pronounced  “dis” + “FAY” + “jee” + “uh”), which means difficulty swallowing. TIGLUTIK was created by scientific experts to flow smoothly using advanced drug suspension technology. It has a mildly thick consistency and designed to be easy to swallow.

TIGLUTIK is for People Who Have a Feeding Tube (PEG Tube)

Crushed tablets are the most common cause of PEG tubes getting clogged and occurs in about 35% of patients. TIGLUTIK is the only formulation of riluzole approved for use with a PEG tube. TIGLUTIK conveniently allows patients to get their prescribed dose of riluzole. Most importantly, it eliminates the risk of crushed tablets clogging their feeding tube.

Ask Your Doctor if TIGLUTIK is Right for You

How Do You Take Your Medication?

Oral

(by mouth)

Click to print information on TIGLUTIK and discuss with your doctor

Click to download PDF

PEG Tube

(by feeding tube)
Click to print information on TIGLUTIK and discuss with your doctor

Click to download PDF

Do You Have Difficulty Swallowing?

Here are two questionnaires that can help your doctor determine if you have difficulty swallowing pills or have general difficulty swallowing. Click inside the box to printout the questionnaires. Bring the completed forms with you to your next doctor’s appointment to discuss your results.

PILL-5

Click to download PDF

EAT-10

Click to download PDF

For additional information about TIGLUTIK as well as information about support programs and additional resources, please go to www.TIGLUTIK.com.

Information may not print correctly using the Firefox web browser. To print information, use either Chrome or Safari web browsers.

Important Safety Information

  • You should not take TIGLUTIK if you are allergic to any of its ingredients.
  • TIGLUTIK can cause liver injury, including death. Your doctor should do blood tests to check your liver function before and during your treatment and may stop treatment with TIGLUTIK if liver function is not normal. Contact your doctor immediately if you have unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, or jaundice and/or dark urine.
  • Call your doctor immediately if you have a fever, cough, or difficulty in breathing while taking TIGLUTIK.
  • If you miss or skip a dose of TIGLUTIK, do not take any extra dose to make up for those you missed, but take your prescribed dose at the next regularly scheduled time.
  • The most common side effects of TIGLUTIK that occurred during medical studies were numbness/ tingling around the mouth, weakness, nausea, decreased lung function, high blood pressure, and abdominal pain. If any side effects become troublesome, contact your doctor.
  • Be sure to tell your doctor and pharmacist about all other health conditions you have and all medicines you are taking, including nonprescription products and vitamins. If you have questions, please talk to your doctor.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-332-1088.

Please click here for the Full Prescribing Information.